FUSION ANTIBODIES PLC Logo

FUSION ANTIBODIES PLC

CRO providing end-to-end services for preclinical antibody development.

FAB | IL

Overview

Corporate Details

ISIN(s):
GB00BDQZGK16
LEI:
213800KBAYRC9VOQ9V39
Country:
United Kingdom
Address:
1 SPRINGBANK ROAD, BT17 0QL BELFAST

Description

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-19 08:25
Update on negotiations with NCI regarding OptiMAL
English 17.5 KB
2025-12-16 12:15
Launch of OptiMAL platform
English 16.2 KB
2025-12-11 08:25
Mammalian Display video
English 24.5 KB
2025-11-25 13:25
Holding(s) in Company
English 21.0 KB
2025-11-24 08:15
Half-year Financial Report
English 225.3 KB
2025-11-21 08:25
Notice of Results
English 17.0 KB
2025-11-13 08:30
OptiMAL Library video
English 16.9 KB
2025-11-03 08:20
OptiMAL® R&D Update
English 16.5 KB
2025-10-27 16:38
Holding(s) in Company
English 22.0 KB
2025-10-16 14:31
Result of AGM
English 15.7 KB
2025-10-16 08:00
AGM statement and H1 trading update
English 17.4 KB
2025-09-19 13:58
Posting of Annual Report & Notice of AGM
English 14.2 KB
2025-09-17 08:00
OptiMAL R&D Update
English 21.3 KB
2025-09-08 08:00
Belfast investor presentation
English 15.2 KB
2025-09-04 08:00
Final Results
English 439.7 KB

Automate Your Workflow. Get a real-time feed of all FUSION ANTIBODIES PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for FUSION ANTIBODIES PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for FUSION ANTIBODIES PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.